Rafael Holdings, Inc.: Business Overview, Financials & Competitive Analysis
Rafael Holdings, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Early-stage biotech portfolio player with clinical inflection potential but challenged by valuation and market positioning requiring successful Phase 3 outcomes for trajectory shift. Early-stage biotech with two Phase 3 trials and promising candidates, but extremely low stock valuation (~$1.18), underperformance vs. industry, and significant shareholder dilution indicate execution risk.
What is Rafael Holdings, Inc.'s industry? Rafael Holdings, Inc. (rafaelholdings.com) operates in Biotechnology / Pharmaceutical Development. AskCyborg classifies Rafael Holdings, Inc. under Biotechnology / Pharmaceutical Development in its company registry.
Rafael Holdings primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It is a clinical stage biotechnology company focused on...
Cyborg Score thesis
Early-stage biotech portfolio player with clinical inflection potential but challenged by valuation and market positioning...
Read the full analyst-debate transcript →Get the Latest Rafael Holdings, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeRafael Holdings, Inc. Overview
Pro stress-test →Rafael Holdings primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It is a clinical stage biotechnology company focused on helping patients with difficult to treat diseases.
Strategic Profile
Pro stress-test →The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. With multiple clinical programs ongoing including two Phase 3 trials, the company is transitioning from clinical-stage toward a commercial enterprise.
Competitive Landscape
Pro stress-test →Rafael competes in the early-stage oncology and rare disease therapeutics space against larger pharma companies and clinical-stage biotech peers. The company underperformed the US Pharmaceuticals industry which returned 24.8% over the past year. Differentiation relies on portfolio of metabolic cancer therapies and rare disease treatments, but faces typical biotech execution risks.
Industry Context
Rafael Holdings, Inc. operates in Biotechnology / Pharmaceutical Development.
Key facts
Founded: 2017 · Headquarters: Newark, New Jersey, United States · Employees: Unknown · Revenue: Limited/Early stage · Market cap: $50M-$75M